MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5114/pg.2025.156473

Медицинская библиотека · Przeglad gastroenterologiczny · 2025

One-year single-center follow-up study of ustekinumab and vedolizumab use in inflammatory bowel disease Egyptian patients as second-line therapy after anti-TNF failure.

Kamel Shimaa, Alaty Waleed Hamed Abd, Rashad Heba, Fathy Dina, Abdel-Samiee Mohamed, Hindy Ibrahim, Shaban Ahmed, Askar Safaa

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Inflammatory bowel disease (IBD) is mainly treated medically, especially with the availability of biological agents. Although anti-TNF drugs have been the only biological drugs available to treat ulcerative colitis (UC) and Crohn's disease (CD) patients for too many years, recently novel biological therapies have been approved for therapy. Using these novel agents as second-line biological therapies has proven to have a good effect on the induction and maintenance of remission of these diseases.

AIM: To evaluate the effectiveness of second-line biologics (ustekinumab and vedolizumab) after an anti-TNF agent failure.

MATERIAL AND

METHODS

From 50 IBD patients receiving biological therapy, 26 patients with severe UC and CD receiving vedolizumab and ustekinumab for 1 year were chosen for this observational and cross-sectional study.

RESULTS

80% of CD patients received vedolizumab, while 75% of UC patients received ustekinumab. UC activity as indicated by the Mayo Scoring Index significantly decreased during follow-up, while CD activity as indicated by Crohn's Disease Activity Index (CDAI) did not significantly decrease with the rise of inflammatory markers, which could be due to the small number of IBD patients who received vedolizumab and ustekinumab.

CONCLUSIONS

There was superior effectiveness of ustekinumab compared to vedolizumab in treating UC patients with prior anti-TNF treatment failure.

Для цитирования: Kamel Shimaa, Alaty Waleed Hamed Abd, Rashad Heba, Fathy Dina, Abdel-Samiee Mohamed, Hindy Ibrahim, Shaban Ahmed, Askar Safaa. One-year single-center follow-up study of ustekinumab and vedolizumab use in inflammatory bowel disease Egyptian patients as second-line therapy after anti-TNF failure.. Przeglad gastroenterologiczny. 2025. DOI: 10.5114/pg.2025.156473.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.